Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% returns, respectively, over the same period. The fund underperformed while the S&P 500 and Nasdaq-100 posted their best quarter in six years. A significant factor in this decline is a ~30% concentration in Alphabet stock, which shifted from a cash-generating asset to a capital-intensive posture following a major stock offering to fund data centers. The performance of the fund was further hampered by losses in AI semiconductor stocks like AMD and Intel, which were sold prematurely. The letter concluded with a commitment to risk management while acknowledging the possibility of mistakes in investment strategy. In addition, please check the fund’s top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Insiders Fund highlighted Cencora (NYSE:COR). Cencora (NYSE:COR) is a global pharmaceutical sourcing and distribution services company serving healthcare providers and manufacturers. On August 13, 2026, Cencora, Inc. (NYSE:COR) closed at $310.01 per share. The one-month return of Cencora, Inc. (NYSE:COR) was 0.49%, and its shares gained 5.67% over the past 52 weeks. Cencora, Inc. (NYSE:COR) has a market capitalization of $59.16 billion.
Insiders Fund stated the following regarding Cencora, Inc. (NYSE:COR) in its Q2 2026 investor letter:
Business: Cencora, Inc. (NYSE:COR) formerly known as AmerisourceBergen, is a top-tier global pharmaceutical solutions leader and a top 10 Fortune 500 company. Generating over $300 billion in annual revenue, Cencora anchors the global healthcare supply chain by facilitating secure, reliable distribution of pharmaceuticals and health products. The company partners with manufacturers, care providers, and pharmacies across the value chain to optimize market access to critical medical therapies. Cencora recently expanded its clinical reach by completing the major acquisition of OneOncology, boosting its specialized U.S. Healthcare Solutions infrastructure.
Insider Buying/Selling: Mark Durcan made two separate purchases totaling 8,000 shares for a combined amount of $2,161,800: 2026-06-18: Purchased 4,000 shares at $274.19 per share (Total: $1,096,760) 2026-05-28: Purchased 4,000 shares at $266.26 per share (Total: $1,065,040) Lauren Tyler made one purchase of 550 shares for a total of $148,627 on 2026-06-22…” (Click here to read the full text)
Cencora, Inc. (NYSE:COR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 61 hedge fund portfolios held Cencora, Inc. (NYSE:COR) at the end of the first quarter, the same as in the previous quarter. While we acknowledge the risk and potential of Cencora, Inc. (NYSE:COR) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Cencora, Inc. (NYSE:COR) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Cencora, Inc. (NYSE:COR) and shared Carillon Eagle Mid Cap Growth Fund’s insight on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
